You Lü
YOU?
Author Swipe
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: USP32 facilitates tumor development and is correlated with poor clinical outcomes in hepatocellular carcinoma patients and is modulated by the E2F7/miR-218-5p axis
USP32 facilitates tumor development and is correlated with poor clinical outcomes in hepatocellular carcinoma patients and is modulated by the E2F7/miR-218-5p axis Open
View article: Fecal microbiota transplantation plus immune checkpoint inhibitor rechallenges in patients with advanced non-small cell lung cancer: a single-arm exploratory study
Fecal microbiota transplantation plus immune checkpoint inhibitor rechallenges in patients with advanced non-small cell lung cancer: a single-arm exploratory study Open
The results indicated that the combined therapy of FMT and immunotherapy rechallenge was feasible and demonstrated a tolerable safety profile in this small cohort. The observed clinical activity is preliminary. These findings support the n…
View article: AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC
AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC Open
View article: [Expression of Concern] Downregulation of miR‑145 contributes to lung adenocarcinoma cell growth to form brain metastases
[Expression of Concern] Downregulation of miR‑145 contributes to lung adenocarcinoma cell growth to form brain metastases Open
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that, regarding the cell migration and invasion assay experiments shown in Fig. 4, the 'Mock' data panel in Fig. 4A‑a (A549 cell lin…
View article: Improving the efficacy of late-line immunotherapy for advanced esophageal cancer: the addition of local radiotherapy
Improving the efficacy of late-line immunotherapy for advanced esophageal cancer: the addition of local radiotherapy Open
Background: The advent of immunotherapy has significantly revolutionized therapies for advanced esophageal cancer (EC). However, clinical data on combining immune checkpoint inhibitors (ICIs) and radiotherapy (RT) in advanced EC remain ins…
View article: The Effect of Integrated Management under 8S Mode on the Detection Rate of MDROs and the Qualified Rate of ICU High-frequency Contact Objects
The Effect of Integrated Management under 8S Mode on the Detection Rate of MDROs and the Qualified Rate of ICU High-frequency Contact Objects Open
Objective: To explore the effect of integrated management under 8S mode on the detection rate of MDROs and the qualified rate of articles in ICU high-frequency contact objects, so as to improve the medical quality of hospitals and the safe…
View article: Combining immune checkpoint inhibitors with thoracic radiotherapy enhances outcomes in advanced non-small-cell lung cancer: a real-world study
Combining immune checkpoint inhibitors with thoracic radiotherapy enhances outcomes in advanced non-small-cell lung cancer: a real-world study Open
Background We aimed to evaluate the efficacy of thoracic radiotherapy (TRT) combined with immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC) in real-world clinical settings and identify predict…
View article: Dynamic evolution and antitumor mechanisms of CXCR6+CD8+ T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy
Dynamic evolution and antitumor mechanisms of CXCR6+CD8+ T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy Open
This study delineates the change trajectory of CD8+ T cells, identifies the crucial role of DCs in T cell differentiation, and highlights the significance of tumor-specific CXCR6+CD8+ T cells in anti-tumor …
View article: Engineering heterogeneous microstructures for enhanced strength and ductility in air-cooled Al−Mg−Si alloys
Engineering heterogeneous microstructures for enhanced strength and ductility in air-cooled Al−Mg−Si alloys Open
View article: Epidemiological and clinical characteristics of COVID-19 mortality: a retrospective study
Epidemiological and clinical characteristics of COVID-19 mortality: a retrospective study Open
Background The global impact of SARS-CoV-2 and its associated coronavirus disease (COVID-19) has necessitated urgent characterization of prognostic biomarkers. This study aimed to delineate the epidemiological and clinical predictors of mo…
View article: A Survey of Fuzzing Open-Source Operating Systems
A Survey of Fuzzing Open-Source Operating Systems Open
Vulnerabilities in open-source operating systems (OSs) pose substantial security risks to software systems, making their detection crucial. While fuzzing has been an effective vulnerability detection technique in various domains, OS fuzzin…
View article: Therapeutic and Diagnostic Potential of MicroRNAs in Children with Attention-Deficit Hyperactivity Disorder
Therapeutic and Diagnostic Potential of MicroRNAs in Children with Attention-Deficit Hyperactivity Disorder Open
View article: Government ESG and corporate green innovation: The moderating effect of internal and external factors
Government ESG and corporate green innovation: The moderating effect of internal and external factors Open
View article: Integrated Metabolome and Transcriptome Analysis Revealed the Mechanism of Secondary Metabolite Biosynthesis in Bletilla striata under UV-C Treatment
Integrated Metabolome and Transcriptome Analysis Revealed the Mechanism of Secondary Metabolite Biosynthesis in Bletilla striata under UV-C Treatment Open
View article: TransBench: Breaking Barriers for Transferable Graphical User Interface Agents in Dynamic Digital Environments
TransBench: Breaking Barriers for Transferable Graphical User Interface Agents in Dynamic Digital Environments Open
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
Purpose:Low-dose radiation therapy (LDRT) may enhance the synergistic anti-tumor effect of combined immunotherapy and stereotactic body radiation therapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluat…
View article: Corrosion behavior of 2A97 Al−Cu−Li alloys in different thermomechanical conditions by quasi-in-situ analysis
Corrosion behavior of 2A97 Al−Cu−Li alloys in different thermomechanical conditions by quasi-in-situ analysis Open
View article: Growth pattern, growth deceleration, and relevant predictors in girls treated with GnRHa: a retrospective longitudinal study
Growth pattern, growth deceleration, and relevant predictors in girls treated with GnRHa: a retrospective longitudinal study Open
Objectives This study aimed to analyze the height growth pattern and the incidence of significant growth deceleration in girls with CPP and EFP on GnRHa treatment, and thereby identify relevant predictors of growth deceleration. Methods Th…
View article: KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review Open
Rat sarcoma virus (RAS) GTPase is one of the most important drivers of non-small cell lung cancer (NSCLC). RAS has three different isoforms (Harvey rat sarcoma viral oncogene homolog [HRAS], Kirsten rat sarcoma viral o…
View article: Metformin prevents the onset and progression of intervertebral disc degeneration: New insights and potential mechanisms (Review)
Metformin prevents the onset and progression of intervertebral disc degeneration: New insights and potential mechanisms (Review) Open
Metformin has been the go‑to medical treatment for addressing type 2 diabetes mellitus (T2DM) as a frontline oral antidiabetic. Obesity, cancer and bone deterioration are linked to T2DM, which is considered a metabolic illness. Numerous di…
View article: 194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results
194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results Open
The phase III CASPIAN trial established D+ EP as first-line (1L) standard of care of ES-SCLC. However, most patients (pts) do not experience durable clinical benefit. LDRT could induce local control, and exert synergistic efficacy with Imm…
View article: Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC Open
View article: The relationship between small for gestational age infants and maternal health: a meta-analysis
The relationship between small for gestational age infants and maternal health: a meta-analysis Open
Maternal risk factors, including BMI, smoking, pregestational diabetes, gestational diabetes, gestational hypertension, and preeclampsia, are associated with SGA.
View article: 867 Embedding partial SBRT in low-dose radiotherapy (EclipseRT) plus immune checkpoint inhibitors for bulky tumors: a preclinical and clinical study
867 Embedding partial SBRT in low-dose radiotherapy (EclipseRT) plus immune checkpoint inhibitors for bulky tumors: a preclinical and clinical study Open
Background Inoperable bulky tumors remain challenging to treat with chemotherapy, radiotherapy (RT) or immune checkpoint inhibitors (ICIs). We developed a novel RT technique with eclipse-shaped dose distribution (EclipseRT, ERT) by embeddi…
View article: MA13.05 Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
MA13.05 Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study Open
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
Purpose:Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the …